| Followers | 28 |
| Posts | 22061 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Wednesday, April 01, 2026 4:18:15 PM
Personalis to Participate in the 25th Annual Needham Virtual Conference
April 1, 2026 4:01 PM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20260401441917/en/
Investor Relations:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
Original: Personalis to Participate in the 25th Annual Needham Virtual Conference
Recent PSNL News
- Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 • Business Wire • 06/02/2026 10:00:00 AM
- Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium • Business Wire • 05/26/2026 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:04:03 PM
- Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring • Business Wire • 05/20/2026 10:00:00 AM
- Personalis to Participate in Upcoming Investor Events • Business Wire • 05/14/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:52:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:03:04 PM
- Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors • Business Wire • 05/13/2026 10:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/12/2026 08:28:07 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/07/2026 09:01:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:03:48 PM
- Personalis Reports First Quarter Results and Recent Highlights • Business Wire • 05/07/2026 08:01:00 PM
- Personalis to Announce First Quarter 2026 Financial Results • Business Wire • 04/23/2026 08:01:00 PM
- Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026 • Business Wire • 04/21/2026 10:00:00 AM
- Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026 • Business Wire • 04/13/2026 10:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 08:07:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 08:03:19 PM
- Personalis to Participate in the 25th Annual Needham Virtual Conference • Business Wire • 04/01/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:57:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:54:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 08:17:21 PM
- Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption • Business Wire • 03/17/2026 08:00:00 PM
